Verseon to Present New Preclinical Safety and Tolerability Results at the 2016 American Heart Association's Scientific Sessions
Using its proprietary, computer-driven discovery platform, Verseon designs drug candidates that are unlikely to be found by traditional drug discovery methods. The Company is advancing a class of potent, highly selective direct thrombin inhibitors that bind to thrombin through a unique mode of action via reversible covalent inhibition.
In preclinical research, Verseon's direct thrombin inhibitors show bioavailability comparable to or better than currently available anticoagulants, suggesting that they may be suitable for oral dosing. In addition, preclinical testing indicates that these inhibitors carry lower bleeding risk compared to existing anticoagulants. The Company believes that this novel class of anticoagulants could provide new therapies for thrombotic disorders with enhanced benefit-risk profiles.
Details of the poster, to be revealed at the American Heart Association conference, are as follows:
Poster Title: Novel, Highly Selective Direct Thrombin Inhibitors: Efficacy, Safety, and Tolerability Studies
Poster Number: T1204
Session Name: Thrombosis, Immunity and Inflammation
Date and Time: November 15, 2016, 12:45-2:00 PM
Location: Science and Technology Hall, Basic Science Section
Verseon Corporation (www.verseon.com, AIM: VSN) is a technology-based pharmaceutical company that employs its proprietary, computational drug discovery platform to develop novel therapeutics that are unlikely to be found using conventional methods. The Company is applying its platform to a growing drug pipeline and currently has three active drug programs in the areas of anticoagulation, diabetic macular edema, and oncology.